Original investigationIncremental Value of 111-In Pentetreotide (cas 138661-02-6) SPECT/CT Fusion Imaging of Neuroendocrine Tumors

Add time:09/07/2019    Source:sciencedirect.com

Rationale and ObjectivesHybrid single photon-emission computed tomographic (SPECT) and computed tomographic (CT) imaging for the investigation of neuroendocrine tumors allows the fusion of functional and anatomic information in a rapid and efficient method. The aim of this study was to assess the incremental diagnostic value of 111In Pentetreotide (cas 138661-02-6) SPECT/CT imaging compared with traditional planar and SPECT imaging with respect to lesion localization and characterization and reader confidence.

We also recommend Trading Suppliers and Manufacturers of Pentetreotide (cas 138661-02-6). Pls Click Website Link as below: cas 138661-02-6 suppliers

Prev:Notas clínicas111In-Pentetreotide (cas 138661-02-6) uptake in a follicular adenoma of the thyroid gland: a pitfall for 111In-Pentetreotide (cas 138661-02-6) scintigraphyCaptación de 111in-pentetreotida en un adenoma folicular de la glándula tiroides: falso positivo en la gammagrafía con 111in-pentetreotida
Next:Original articleValidation of stationary phases in 111In-Pentetreotide (cas 138661-02-6) planar chromatographyValidación de fases estacionarias en la cromatografía planar de 111In-pentetreótida☆)